22138-73-4

Usage

Uses

Used in Pharmaceutical Industry:
4-Fluoro-alpha-methyl-benzenepropanic acid is used as a key intermediate in the synthesis of various pharmaceutical compounds for its potential therapeutic properties. It plays a crucial role in the development of new drugs targeting a range of medical conditions.
Used in Research Applications:
In the research field, 4-FMPA is employed as a chemical probe to study the effects of its molecular structure on biological systems, particularly in understanding its impact on the central nervous system and neurotransmitter levels.
Used in Drug Development:
4-Fluoro-alpha-methyl-benzenepropanic acid is used as a precursor in drug development for the creation of novel therapeutic agents that may have applications in treating neurological disorders or other conditions influenced by serotonin and dopamine levels.
Used in Controlled Substances Regulation:
Due to its potential for abuse and addiction, 4-FMPA is also used in the context of controlled substances regulation, where it is monitored and restricted to prevent misuse and ensure that its benefits are realized within a safe and ethical framework.

Upstream product

• 22138-72-3 (E)-3-(4-fluorophenyl)-2-methylacrylic acid 
• 29417-80-9 Methyl-2-methyl-3-p-fluorphenylpropionat 
• 22138-72-3 3-(4-fluorophenyl)-2-methylacrylic acid 
• 459-57-4 4-fluorobenzaldehyde 

Downstream Products

• 37794-19-7 6-fluoro-2-methylindanone 
• 1346513-25-4 C₂₅H₂₇FO₂ 
• 1346513-28-7 C₂₀H₁₄F₄O₂ 
• 1346513-26-5 C₂₃H₂₃FO₂ 
• 1346513-42-5 C₂₄H₁₈FNO₂ 
• 1346513-27-6 C₂₁H₁₉FO₃ 
• 1346513-30-1 C₂₀H₁₄FNO₂ 
• 1346513-32-3 C₂₁H₂₀FNO₂ 

Relevant academic research and scientific papers

Weak, bidentate chelating group assisted cross-coupling of C(sp3)-H bonds in aliphatic acid derivatives with aryltrifluoroborates

A protocol of Pd(ii)-catalyzed, weak bidentate directing group assisted β-C(sp3)-H activation/cross-coupling with organoboron reagents has been achieved, affording arylation of aliphatic acid derivatives that contain α-hydrogen atoms in moderate to good yields. The potential of this method for an asymmetric β-C(sp3)-H arylation via desymmetrization was also presented.

Preparation method for indanone compound

The invention especially relates to a preparation method for an indanone compound, belonging to the field of organic synthesis. The preparation method for the indanone compounds comprises the following steps: 1) subjecting a compound as shown in a formula I and a compound as shown in a formula II to a condensation reaction so as to prepare a compound as shown in a formula III; 2) subjecting the compound as shown in the formula III to hydrolysis in the presence of alkali so as to prepare a compound as shown in a formula IV; and 3) carrying out acylation and ring closure on the compound as shownin the formula IV so as to prepare the as shown in a formula V. Compared with the prior art, the preparation method for the indanone compound in the invention has the advantages of low raw material cost, simple operation, low production of waste water, waste gas and industrial residues, high yield and the like, and is more suitable for industrial production; and compared with various traditionalpreparation methods for the indanone compound, the preparation method of the invention has obvious advantages and shows good industrialization prospects.

COMPOUNDS, COMPOSITIONS AND METHODS OF TREATING CANCER

Disclosed are compounds of formulas I and II, in which R, R0, R1-R4, R7-R10, n, X, Y, Y', and E are as described herein, pharmaceutical compositions containing such compounds. The compounds and pharmaceutical compositions are for use in treating or preventing diseases, for example, cancer.

INDENYL COMPOUNDS, PHARMACEUTICAL COMPOSITIONS, AND MEDICAL USES THEREOF

Disclosed are compounds, for example, compounds of formula I, wherein R, R0, R1-R8, n, X, Y, Y′, and E are as described herein, pharmaceutical compositions containing such compounds, and methods of treating or preventing a disease or condition, for example, cancer.

METHOD OF TREATING OR PREVENTING RAS-MEDIATED DISEASES

Disclosed are compounds, for example, a compound of formula I, wherein R, R0, R1-R8, n, X, Y, Y′, and E are as described herein, pharmaceutical compositions containing such compounds, and methods of treating or preventing a disease or condition for example, cancer, mediated by the ras gene.

METHODS AND COMPOSITIONS RELATED TO A RETINOID RECEPTOR-SELECTIVE PATHWAY

Provided herein are methods and compositions related to a retinoid receptor-selective pathway. As described herein, this pathway can be targeted to manipulate a tumor microenvironment. For example, the methods and compositions described herein can be used to induce apoptosis in a cancer cell. Further, the compositions described herein, including Sulindac and analogs thereof, can be used to target this pathway for the treatment or prevention of cancer in human patients.

Synthesis and SAR study of modulators inhibiting tRXRα-dependent AKT activation

RXRα represents an intriguing and unique target for pharmacologic interventions. We recently showed that Sulindac and a designed analog could bind to RXRα and modulate its biological activity, including inhibition of the interaction of an N-terminally truncated RXRα (tRXRα) with the p85α regulatory subunit of phosphatidylinositol-3-OH kinase (PI3K). Here we report the synthesis, testing and SAR of a series of novel analogs of Sulindac as potential modulators for inhibiting tRXRα-dependent AKT activation. A new compound 30 was identified to have improved biological activity.

Method for treating a patient with neoplasia using Iressa

This invention provides a method for treating a patient with neoplasia by an adjuvant therapy that includes treatment with an inhibitor of human epidermal growth factor receptor tyrosine kinase and a cGMP-specific phosphodiesterase inhibitor.

Methods for treatment of lupus erythematosus

Substituted condensation products of N-benzyl-3-indenylacetamides with heterocyclic aldehydes and other such inhibitors are useful for the treatment of lupus erythematosus.

Methods for treatment of multiple sclerosis

Substituted condensation products of N-benzyl-3-indenylacetamides with heterocyclic aldehydes and other such inhibitors are useful for the treatment of multiple sclerosis.